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NPC1161B, an 8-Aminoquinoline 
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falciparum Oocyst Maturation
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Malaria is a major global health threat, with nearly half the world’s population at risk of 
infection. Given the recently described delayed clearance of parasites by artemisinin-
combined therapies, new antimalarials are needed to facilitate the global effort toward 
elimination and eradication. NPC1161 is an 8-aminoquinoline that is derived from 
primaquine with an improved therapeutic profile compared to the parent compound. 
The (R)-(−) enantiomer (NPC1161B) has a lower effective dose that results in decreased 
toxic side effects such as hemolysis compared to the (S)-(+)-enantiomer, making it a 
promising compound for consideration for clinical development. We explored the effect 
of NPC1161B on Plasmodium falciparum oocyst and sporozoite development to evaluate 
its potential transmission-blocking activity viz. its ability to cure mosquitoes of an ongoing 
infection. When mosquitoes were fed NPC1161B 4 days after P. falciparum infection, we 
observed that total oocyst numbers were not affected by NPC1161B treatment. However, 
the sporozoite production capacity of the oocysts was impaired, and salivary gland 
sporozoite infections were completely blocked, rendering the mosquitoes non-infectious. 
Importantly, NPC1161B did not require prior liver metabolism for its efficacy as is required 
in mammalian systems, suggesting that an alternative metabolite is produced in the 
mosquito that is active against the parasite. We performed liquid chromatography–mass 
spectrometry (LC-MS)/MS analysis of methanol extracts from the midguts of mosquitoes 
fed on an NPC1161B (434.15 m/z)-treated blood meal and identified a compound with 
a mass of 520.2 m/z, likely a conjugate of NPC1161B or an oxidized metabolite. These 
findings establish NPC1161B, and potentially its metabolites, as transmission-blocking 
candidates for the treatment of P. falciparum.
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INTRODUCTION
Malaria is a devastating disease that globally affects over 200 
million people annually and caused over 435,000 deaths in 
2017, mostly in children under the age of five. Despite the 
significant progress made in recent years, global malaria 
control has stagnated between 2015 and 2017 (WHO, 2017). 
Plasmodium falciparum, Plasmodium vivax, Plasmodium 
ovale, Plasmodium malariae, and Plasmodium knowlesi are 
the causative agents of malaria in humans, with P. falciparum 
being the most lethal. Plasmodia are transmitted by anopheline 
mosquito vectors. When the mosquito takes a blood meal, 
Plasmodium sexual stage gametocytes transition into male and 
female gametes, which fertilize and develop into the motile 
ookinete. Ookinetes invade the mosquito midgut to form an 
oocyst, which functions as the sporozoite production site. 
The development of each oocyst leads to the production of 
thousands of sporozoites, which then invade the salivary glands 
of the mosquito, making the mosquito capable of transmitting 
parasites during its next blood meal (Al-Olayan et al., 2002; 
Zollner et al., 2006; Nacer et al., 2008).
Current front-line malaria treatments focus on eliminating 
the asexual blood stages of the parasite; however, even after 
asexual parasites are eliminated, the gametocytes can persist, 
allowing transmission to new mosquito vectors (Tangpukdee 
et al., 2008). A natural bottleneck in parasite number occurs in 
the mosquito, with a minimum in parasite number occurring 
in the oocyst stage, making the sexual stage an appealing target 
for drug intervention to prevent transmission (Vaughan et al., 
1992; Porter-Kelley et al., 2006). As the current antimalarials 
become less effective in Africa and Southeast Asia, alternative 
antimalarial drugs are needed (German and Aweeka, 2008; 
Abdul-Ghani et al., 2017). The 8-aminoquinolines (8AQ) 
have shown potential to fill this need and act as transmission-
blocking drugs for malaria (Tekwani and Walker, 2006; WHO, 
2011; White, 2013).
The 8AQ are the only class of drug that has been approved 
by the Food and Drug Administration (FDA) to clear dormant 
hepatic hypnozoites in patients with P. vivax and P. ovale. 
They are also effective against Plasmodium asexual and sexual 
blood stages and mosquito stages (Tekwani and Walker, 
2006). This versatility in targeting allows these drugs to act as 
prophylactics or as treatment/transmission-blocking agents 
during Plasmodium infections (Tekwani and Walker, 2006). 
For example, primaquine is used as an effective prophylaxis 
for all forms of malaria, as a treatment for P. vivax and P. ovale 
infections, and as a transmission interrupter for P. falciparum 
(Baird and Hoffman, 2004; Hill et al., 2006; Tekwani and Walker, 
2006; WHO, 2011; White, 2013). Tafenoquine (WR 238605), a 
primaquine derivative that was approved by the FDA in 2018 
for the radical cure of relapsing malaria, has also been shown 
to prevent the transition of P. vivax, P. falciparum, Plasmodium 
yoelii, and Plasmodium berghei gametocytes to gametes and 
inhibit sporozoite production of P. vivax and P. falciparum 
(Peters et al., 1993; Ponsa et al., 2003; Walsh et al., 2004). 
However, these 8AQ induce pronounced hemolytic effects 
in glucose-6-phosphate dehydrogenase (G6PD)–deficient 
individuals and may elicit exaggerated responses in NADH 
methemoglobin reductase-deficient individuals and pose 
dangers for pregnant women (Hill et al., 2006). Due to these 
dangers, these drugs cannot provide antimalarial protection for 
everyone, leaving the need for a safe and efficacious antimalarial 
(Nanayakkara et al., 2008).
Primaquine and tafenoquine are used as racemic mixtures 
for the treatment of malaria. Another 8AQ, 8-[(4-amino-
1-met hy lbuty l )amino]-6-met hoxy-4-met hy l -5-[3 ,4-
dichlorophenoxy]quinoline succinate (NPC1161, WR 233078) 
in racemic form (NPC1161C) has shown excellent antimalarial 
activity in animal models (Nanayakkara et al., 2008). In a P. 
berghei model, NPC1161C cleared blood stage parasites and 
was curative within 3 days of oral treatment at 1 mg/kg/day; 
by contrast, tafenoquine required 16 mg/kg/day for 3 days, and 
primaquine was ineffective even at 64 mg/kg/day (Nanayakkara 
et al., 2008). In the mouse causal prophylaxis model, NPC1161B 
is active at 1 mg/kg/day for 3 days, while tafenoquine and 
primaquine require 3 and 20 mg/kg/day for 3 days, respectively 
(Pybus et al., 2013; Marcsisin et al., 2014). NPC1161C has also 
shown potent radical curative activity against Plasmodium 
cynomolgi infection in rhesus monkeys (primaquine index 4.8) 
(Davidson et al., 1981). In some cases, a single enantiomer can 
provide a better therapeutic index than the racemic mixture 
(Nguyen et al., 2006). The (R)-(−)-enantiomer (NPC1161B) 
has less hemolytic toxicity in mice and dogs, and more activity 
against several different parasites in animal models than the 
racemate (NPC1161C) or the (S)-(+)-enantiomer (NPC1161A) 
(Tekwani and Walker, 2006; Nanayakkara et al., 2008).
Studies have documented the importance of human 
cytochrome P450 (CYP) enzymes in the metabolism of 8AQ 
(Ganesan et al., 2009; Myint et al., 2011; Marcsisin et al., 
2014). Specifically, enzyme CYP 2D6 has been suggested to 
play a critical role in the metabolism of primaquine, as well as 
tafenoquine and NPC1161B, into potential active metabolites 
(Bennett et al., 2013; Pybus et al., 2013; Marcsisin et al., 2014). 
Furthermore, NPC1161B had no antimalarial activity in CYP 
2D6-knockout mice infected with P. berghei (Marcsisin et al., 
2014). However, little is known about the metabolism of 8AQ or 
its potential metabolites in non-vertebrate systems. Although 
metabolism of other compounds, such as pyrethroids, has 
been observed in the mosquito vector, no studies have shown 
the metabolism of 8AQ by mosquitoes (Ibrahim et al., 2016). 
NPC1161B can prevent exflagellation events in in vitro P. 
falciparum gametocyte cultures, and oocyst development and 
sporogony in P. berghei and P. falciparum in vivo systems, 
suggesting that NPC1161B does not need CYP-mediated 
metabolism to derive antimalarial transmission-blocking 
activity (Delves et al., 2012).
Here, we report the use of NPC1161B to disrupt P. falciparum 
sporogonic development in Anopheles stephensi mosquitoes 
with an ongoing P. falciparum infection. Additionally, we 
provide evidence that NPC1161B metabolites are produced in 
the mosquito midgut following ingestion of NPC1161B-treated 
blood meal over the 48-h period of blood digestion. 
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RESULTS
NPC1161B Has A Significant Effect On 
Oocyst Development
We first determined whether NPC1161B had an effect on oocyst 
development, and whether metabolism by a vertebrate host 
was essential for such effects. To address these questions, An. 
stephensi mosquitoes were infected with P. falciparum using 
a standard membrane feeding assay (SMFA). A dose of 10 μM 
NPC1161B was either provided in the infectious blood meal or 
4 days later in a second uninfected blood meal. Previous work 
demonstrated that the 10 μM dose could inhibit P. falciparum 
gametocyte exflagellation and subsequent oocyst development 
when added to in vitro parasite cultures (Delves et al., 2012). 
On day 8 after infection, mosquito midguts were dissected and 
either stained with 0.1% mercurochrome for oocyst enumeration 
or probed with anti-PfCSP antibody and 4′,6-diamidino-2-
phenylindole (DAPI) nuclear stain. We observed that NPC1161B, 
when administered at the time of infection, significantly reduced 
oocyst intensity (P = 0.0040; two-tailed t-test) in the mosquitoes 
(Figure 1A); this is akin to what has been described previously 
for tafenoquine; however, NPC1161B treatment at day 4 post-
infection did not show a significant difference (P = 0.4935; two-
tailed t-test) between the number of oocysts observed on the 
control- and NPC1161B-treated midguts (Figure 1B), showing 
that once oocyst development has been initiated (between 24 and 
48 h post-infection), NPC1161B does not affect oocyst numbers 
(Ponsa et al., 2003). We did observe a trend toward a reduction 
FIGURE 1 | NPC1161B (10 μM) can significantly reduce oocyst number and reduces oocyst size. (A) NPC1161B (10 μM) or carrier solvent was administered 
at the time of infection. The midgut oocyst number was enumerated at day 8 post-infection; a representative replicate is shown. (B) NPC1161B (10 μM) or 
carrier solvent was administered at day 4 post-infection. The oocyst number was enumerated at day 8 post-infection; a representative replicate is shown. 
(C–D) NPC1161B (10 μM) or carrier solvent was administered at day 4 post-infection, and oocyst diameter was evaluated at day 8 post-infection. Representative 
experiments are shown. (N = 20 mosquitoes/group).
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in oocyst diameter with 10 μM NPC1161B treatment on day 4 
post-P. falciparum infection; however, the statistical significance 
of this trend was inconsistent (Figures 1C, D).
NPC1161B Affects Sporozoite 
Development In Oocysts
Having shown that NPC1161B affects oocyst size but did not 
alter the number when given 4 days post-infection, we set out 
to study whether NPC1161B would have an effect on the oocyst 
to sporozoite transition. We administered NPC1161B (10 µM) 
by membrane feeding at day 4 post-infection and monitored 
the phenotype of oocyst development using a whole-mount 
midgut immunofluorescence assay and salivary gland sporozoite 
enumeration. Oocyst development and maturation on the basal 
midgut wall are intrinsically asynchronous. As expected, at day 
11 post-infection, oocysts that developed without exposure to 
NPC1161B had already released sporozoites (Figures 2A, B). This 
was not observed in mosquitoes exposed to NPC1161B (Figures 
2C, D), suggesting that oocyst maturation was arrested. We also 
observed a wider range of oocyst diameters in the NPC1161B-
treated mosquitoes than in the control-treated mosquitoes 
(Figures 2A–D), thus corroborating our previous data (Figures 
1C, D). DAPI staining of nuclei indicated that, regardless of 
size, punctate or partitioned DNA was readily observed even in 
smaller oocysts in the treatment group, indicative of sporoblast 
initiation (Ganter et al., 2017). However, we did observe weaker 
PfCSP staining in NPC1161B-treated midguts compared with 
the carrier-treated controls, suggesting that there was a defect 
in oocyst maturation or typical developmental pathways. At 
day 14 post-infection (day 10 post-NPC1161B treatment), 
when the majority of oocysts should have already ruptured, the 
salivary glands were dissected and processed, and the number of 
sporozoites per gland was enumerated. Three blinded replicate 
treatment cohorts demonstrated a significant reduction (P < 
0.001 for carrier vs. each NPC1161B-treated replicate; two-
tailed t-test) in sporozoite number in mosquitoes fed on blood 
with NPC1161B 4 days post-infection, as compared with control 
mosquitoes (Figure 2E).
A Novel NPC1161B Metabolite Is 
Produced In The Mosquito
In light of the finding that NPC1161B is effective at preventing 
P. falciparum development in the mosquito without prior 
metabolism of the compound by mammalian host CYP enzymes, 
we hypothesized that there is metabolism of NPC1161B in the 
mosquito midgut. To understand whether mosquito metabolism 
of NPC1161B contributes to parasite elimination, we used liquid 
chromatography–mass spectrometry (LC-MS) to evaluate the 
metabolites produced in the mosquito midgut after ingestion of a 
blood meal and exposure to NPC1161B. 
To identify potential metabolites of NPC1161B from the 
midgut, we first analyzed the parent drug by product ion scanning 
using a triple quadrupole mass spectrometer (QqQ-MS). In this 
mode, the first quadrupole was used to select for NPC1161B 
(434.15 m/z) eluting from the column, which is fragmented by 
collision-induced dissociation (CID) in the second quadrupole, 
and the resulting ions analyzed in full scan mode (35–500 m/z) 
by the third quadrupole. Injections of NPC1161B were repeated 
in an iterative process to determine the optimal CID energies and 
resulting fragment ions from the parent drug that could be used 
to identify metabolites in the blood meal (Figure 3).
Midguts (n = 10) from uninfected An. stephensi and An. 
gambiae mosquitoes previously fed a blood meal containing 
NPC1161B (10 µM) were dissected at 48 h post-feeding into 
cold methanol for metabolite extraction and subsequent analysis 
by LC-MS. Potential metabolites of NPC1161B produced in 
mosquitoes were then determined by precursor ion scanning 
using a QqQ-MS. In this mode, the first quadrupole was set to 
full scan mode (100–600 m/z), the second quadrupole set to 
fragmentation by CID at 42 eV, and the third quadrupole was 
set to detect only the fragments generated from NPC1161B 
with m/z of 203.2, 215.1, or 334.0. In this way, only compounds 
that gave rise to one or more of these fragments were detected. 
The extracted ion chromatogram (XIC) for the sum of all three 
product ions shows a number of peaks with low intensity that were 
not found to stem from metabolized NPC1161B, likely resulting 
from low abundance of only one or two product ions. However, 
only a single intense peak was observed and determined to likely 
be a metabolite of NPC1161B (Figure S1). This observation was 
based on two factors: 1) all three fragment ions were observed 
and found to stem from a single peak with a mass of 520.2 m/z, 
and 2) the parent ion observed showed a distinctive isotope 
spacing that results from chlorine-containing compounds, such 
as NPC1161B, when analyzed by mass spectrometry. 
Having found a potential metabolite of NPC1161B in 
mosquito midguts, we further characterized this compound 
using high resolution LC-MS. Both the NPC1161B standard and 
the previously analyzed midgut metabolite extract were analyzed 
using quadrupole time-of-flight mass spectrometry (Q-ToF-MS), 
which produces higher resolution data than the QqQ-MS system 
used previously. The mass spectra of both the parent compound 
and resulting metabolite showed the distinctive chlorine isotope 
spacing expected (Figure S2), suggesting that the ion observed 
in the blood meal was likely a metabolite of NPC1161B produced 
in the mosquito midgut. Both ions were then subjected to 
fragmentation by CID, and the resulting patterns showed a high 
degree of similarity, providing further evidence that the two 
compounds were related and that the metabolite originated from 
NPC1161B (Figure 4, summarized in Table 1). Additionally, to 
confirm that the observed metabolite from midgut extracts was 
not the result of direct metabolism by red blood cells (RBCs), 
as has been seen recently for the related 8-AQ primaquine, we 
analyzed extracts from uninfected RBCs that were incubated with 
NPC1161B alone. RBCs were incubated with 10 µM NPC1161B 
for up to 48 h, then extracts were prepared and analyzed as before 
(Fasinu et al., 2019). We did not observe the formation of the 
metabolite previously extracted from midguts (520.2 m/z), and 
in fact, we saw no change in NPC1161B abundance at any of the 
time points analyzed (1, 6, 24, and 48 h).
We next attempted to determine the structure of the NPC1161B 
metabolite. The structure and resulting fragment ion m/z data 
from NPC1161B were submitted to MetFragWeb, an online tool 
that performs in silico fragmentation and structure prediction 
NPC1161B Inhibits Plasmodium SporogonyHamerly et al.
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(Ruttkies et al., 2016). The algorithm takes as input a structure and 
fragment ions and produces formula and predicted structures for 
each fragment ion within a given tolerance. Using the output of 
this search, we were able to putatively match a number of high 
abundance fragment ions from NPC1161B with structures and 
formulas (Figure 5; Table 1; Table S1). Furthermore, many of 
these fragment ions were also present in the metabolite observed 
in the midgut extract. While we could not elicit an accurate 
structure of the metabolite, the major fragment ions of the core 
8AQ structure were present. The observed mass of 520.2 m/z for 
the NPC1161B metabolite is significantly higher than the parent 
compound at 434.15 m/z, suggesting this may be a conjugate of 
NPC1161B, or perhaps a conjugate of an oxidized metabolite. 
At this stage, structural identification is not possible using 
conventional methods. Further analysis by NMR spectroscopy is 
needed to fully elicit a structure for this metabolite.
FIGURE 2 | NPC1161B-derived metabolites block sporozoite development. Mosquitoes were given carrier solvent alone (A-B) or NPC1161B (10 µM) (C-D) at 
day 4 post-infection. Midguts were dissected on day 11 post-infection. The midguts were probed with anti-P. falciparum circumsporozoite protein to identify fully 
formed sporozoites and stained with DAPI to permit visualization of individual sporozoite segmentation. The dotted white lines demarcate the boundaries of oocysts 
captured in the field of view. The white arrows point to a group of sporozoites that were released from a burst oocyst and found fixed to the outside of the midgut. 
(E) NPC1161B (10 µM) or carrier solvent was administered to mosquitoes at day 4 post-infection; salivary glands were dissected, and sporozoites were counted at 
day 14 post-infection. The reduction in sporozoite number for each replicate of NPC1161B treatment (N = 25) as compared to the carrier solvent treatment (N = 25) 
was found to be statistically significant by ANOVA (P < 0.0001).
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FIGURE 3 | Analysis of NPC1161B standard by LC-QqQ-MS. Extracted ion chromatogram for NPC1161B standard (A) and the resulting product ion scan (B). 
Product ion scanning was used to select fragment ions of NPC1161B for downstream precursor ion scanning to determine metabolites of NPC1161B extracted 
from mosquito midguts post-feeding. A 1 µl injection of 100 pg/µl was subjected to fragmentation at 42 eV, where Q1 was set to the parent ion (434.15 m/z), and 
Q3 was set to obtain a full scan from 35 to 500 m/z. Three ions were selected for use in precursor ion scans: 203.1, 215.1, and 334.0 m/z.
FIGURE 4 | Fragmentation analysis of NPC1161B standard and metabolite by LC-QToF-MS. Mass spectra for NPC1161B standard (A) and the metabolite 
identified from mosquito midgut extracts post-blood meal (B) after fragmentation at 42 eV. A number of peaks were found to be shared by both compounds (see 
Table 1).
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DISCUSSION
Transmission-blocking drugs are an essential weapon in 
the fight to eliminate and eradicate malaria (The malERA 
Refresh Consultative Panel On Basic Science And Enabling 
Technologies, 2017). Previous work has established the direct 
antimalarial effects of NPC1161B through its ability to prevent 
P. falciparum exflagellation and subsequent oocyst development 
when added directly to gametocytemic blood (Delves et al., 
2012). Our study extends these findings to shed new light on 
the utility of NPC1161B as a transmission-blocking antimalarial 
that can also be effective when delivered after the establishment 
of infection in the mosquito. The varied DAPI nuclear staining 
observed (Figures 2A–D), the difference in oocyst size (Figures 
1C, D), and the significant difference in sporozoite production 
(Figure  2E) in the NPC1161B-treated mosquitoes compared 
with control-treated mosquitoes suggest that NPC1161B 
disrupts sporozoite development in the oocyst when given at 
10  µm. By preventing the development of sporozoites in the 
oocyst, no sporozoites can be released into the hemolymph 
to invade the salivary glands, and the mosquito can no longer 
transmit the parasite. This suggests that NPC1161B would not 
only be effective in blocking transmission from patients infected 
with Plasmodium by killing gametocytes but may also be effective 
when uninfected individuals are fed upon by mosquitoes that are 
carrying parasites as has been shown previously with the 8AQ 
tafenoquine (Ponsa et al., 2003).
The mechanism of action of the 8AQ like NPC1161B 
remains unclear, but it is likely that they exert their antimalarial 
effects by generating reactive oxygen species and/or interfering 
with the parasite’s electron transport chain. Historically, these 
effects were believed to be due to the metabolites from the 
8AQ (Grewal, 1981). However, previous work with NPC1161B 
suggested that it could affect P. falciparum without any prior 
FIGURE 5 | Mass spectrum showing the fragmentation pattern of NPC1161B annotated with the m/z and predicted chemical formula with structure. The structure 
of NPC1161B is shown with the red region denoting the predicted fragment that matches to a given ion.
TABLE 1 | Fragment ion, predicted formula, and the relative intensity for each 
ion from NPC1161B and its metabolite.
Fragment 
m/z
Predicted formula % Rel. Int. 
NPC1161B 
(434.14 m/z)
% Rel. Int. 
metabolite 
(520.13 m/z)
70.08 [C5H10]+ 11.1 16.3
80.95 – 0.9 2.3
84.08 [C5H11N-H]+ 17.7 –
86.10 [C5H12N]+ 8.0 –
175.09 [C10H10N2O+H]+ 8.6 6.23
187.06 [C11H9NO2]+ 3.8 2.2
203.08 [C11H10N2O2+H]+ 19.5 16.7
215.12 [C13H14N2O+H]+ 11.9 8.35
290.01 – 1.3 1.3
303.04 – 1.6 3.5
318.01 – 2.2 5.3
334.03 [C17H12Cl2NO2+2H]+ 4.1 1.9
345.06 [C18H14Cl2N2O]+H]+ 51.2 12.0
349.05 [C17H13Cl2N2O2+2H]+ 22.0 4.0
360.04 [C18H14Cl2N2O2]+ 22.0 13.5
372.05 – 1.0 2.5
375.07 [C19H17Cl2N2O2]+ 100 100
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metabolism (Delves et al., 2012). Here, we expanded on 
this concept and found that NPC1161B can be metabolized 
uniquely in An. stephensi and An. gambiae mosquitoes 
without the need for mammalian CYP enzymes to activate 
its antimalarial functions. The persistence and dissemination 
of the active metabolites we observed following ingestion of 
an NPC1161B-treated blood meal to affect oocysts maturing 
on the midgut wall are provocative. Interestingly, there was 
no evidence of the parent compound present in the dissected 
midguts, suggesting full metabolism, or potentially excretion, 
within 48 h post-feeding. Determination of the structures of the 
NPC1161B metabolites identified here (Figure 4) could lead 
to the chemical synthesis of these compounds for subsequent 
testing in liver stage assays for P. falciparum and P. vivax, as 
well as for use in murine malaria in vivo models, to determine 
if potency is maintained while subsequently reducing toxicity 
(Roth et al., 2018). 
As the 8AQ are generally associated with hemolytic toxicity 
in G6PD-deficient humans, it would be ideal to find a metabolite 
that could safely be administered (Hill et al., 2006; Nanayakkara 
et al., 2008). An additional option to reduce potential toxicity 
with the parent NPC1161B compound would be to add a 
modification to prevent activation until it is transferred from 
the human bloodstream to the mosquito midgut. Recent work 
has established the feasibility of inserting light-regulated photo 
switches into drug molecules; in the presence of this photo switch, 
the compound would only become active when transferred 
from the darkness of the human bloodstream to the semi-
transparent conditions of the mosquito midgut (Nevola et al., 
2013; Paaijmans and Fernàndez-Busquets, 2014). Alternatively, 
infected mosquitoes could be treated directly with NPC1161B, 
thereby avoiding the potential for toxic side effects in the human 
host. One potential delivery strategy would be to pretreat 
mosquito resting surfaces with the compound. Mosquitoes are 
known to take up atovaquone through their legs, leading to a 
decrease in or even the absence of oocysts following a subsequent 
P. falciparum blood meal (Tenywa et al., 2017; Maia et al., 2018). 
However, other compounds such as pyrimethamine are not taken 
up through the cuticle, and uptake through the legs may hinder 
proper metabolism and decrease the effectiveness of a compound 
like NPC1161B. A more practical approach to treat infected 
mosquitoes is through the use of modified sugar baits containing 
the drug. Attractive-toxic sugar baits are currently used to 
deliver insecticides like ivermectin, and they are inexpensive and 
effective at killing both male and female mosquitoes (Zhu et al., 
2017; Sissoko et al., 2019). However, there is concern over the use 
of insecticides in these baits due to the emergence of resistance in 
mosquito populations (Tenywa et al., 2017; Maia et al., 2018). An 
appealing alternative would be to use these baits to deliver drugs 
that target the pathogen instead of the mosquito. Ingestion of 
NPC1161B from a sugar meal would likely result in metabolism 
via the midgut, as was seen in our study. This delivery method 
is more practical than pretreating surfaces but would require 
further development to ensure drug stability in the field.
In addition to the tolerability profile, it would be ideal for 
a transmission-blocking drug to have efficacy against not only 
P. falciparum but also against the other human malarial parasites. 
NPC1161B has already shown efficacy in both P. falciparum 
and P. berghei, so it will be important to extend these findings, 
particularly to P. vivax (Delves et al., 2012). Using a drug that 
can target multiple Plasmodium species would be advantageous 
in the field, especially in areas where cases of malaria are not 
diagnosed by species-specific rapid diagnostic tests or other 
species-specific methods. 
Overall, there remains a critical need for effective antimalarials 
on the path toward disease eradication. Currently utilized 
antimalarials such as chloroquine-, mefloquine-, pyrimethamine-, 
and artemisinin-based combination therapies are not safe for all 
patients, neither are they efficacious due to the increasing levels 
of resistance among parasites (German and Aweeka, 2008; Abdul-
Ghani et al., 2017). By disrupting sporozoite development in the 
oocyst with NPC11161B treatment, sporozoites can no longer 
invade the salivary glands, therefore ending the cycle of parasite 
transmission. These findings make NPC1161B a promising 




The An. stephensi (SDA500) and An. gambiae (KEELE) colonies 
were raised at 26°C under 70% humidity with equal day–night 
conditions. Adult mosquitoes were sustained with sucrose 
and water.
P. falciparum Standard Membrane 
Feeding Assay 
P. falciparum (NF54) gametocyte cultures were grown under 
hypoxic conditions by combining 0.5% asexual mix with 
4% hematocrit blood in RPMI culture media with HEPES, 
hypoxanthine, glutamine, and 10% human serum, which was 
changed daily during culturing. From day 15 through day 18 post-
seeding, the cultures could be used to infect mosquitoes using 
the standard membrane feeding assay. Approximately 80–100 
An. stephensi were aspirated into cups and starved overnight to 
ensure blood feeding. Mosquitoes were at least 4 days old after 
emerging on the day of infection to optimize feeding but no older 
than 8 days. All materials used to prepare cultures were warmed to 
37°C. Pre-washed blood and culture were centrifuged at 1,800 × g 
for 4 min with the brake on 4 to pellet the uninfected RBCs. The 
RPMI was aspirated from the packed RBCs, and heat-inactivated 
human serum (HIHS) was added to 50% hematocrit, all while 
keeping blood at 37°C. Infected packed RBCs were diluted to 
0.3% gametocytemia with 50% hematocrit uninfected blood. 
Infectious blood remained at 37°C, and 150 μl of infectious blood 
was added to each sealed feeder. The mosquitoes were allowed 
to feed for a minimum of 45 min. When most mosquitoes 
had visibly fed, those that did not feed were removed, and the 
remainder were provided with sucrose and water along with a 
saturated cotton ball and filter paper that allowed for oviposition 
so that the mosquitoes could take another blood meal to receive 
the drug on day 4 post-infection. Mosquitoes were maintained at 
26°C with 70% humidity.
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Administering NPC1161B To Infected 
Mosquitoes
A 10 mM stock of NPC1161B in carrier consisting of 100 μl of 
DMSO, 5 μl of TWEEN-80, 400 μl of PEG-400, and 495 μl of 
sterile de-ionized water was prepared along with the control 
solution of carrier alone. From the 10 mM NPC1161B stock, 1 μl 
was added to 1 ml of 50% hematocrit uninfected blood in HIHS 
for a final concentration of 10 μM NPC1161B. Similarly, 1 μl of 
carrier control was added to 1 ml of 50% hematocrit uninfected 
blood in HIHS. On day 4 post-infection with P. falciparum, the 
experimental group of An. stephensi mosquitoes was fed on 
300 μl of the NPC1161B-treated blood by membrane feeder. 
Microscopy confirmed that direct addition of 10 μM NPC1161B 
to the blood did not cause lysis of the RBCs. The control group of 
An. stephensi mosquitoes was fed on 300 μl of the carrier-treated 
blood by membrane feeder.
To test the blocking capabilities of NPC1161B on P. falciparum’s 
oocyst stage, 1 μl of a 10 mM NPC1161B stock was added 
to 1 ml of 50% hematocrit infected blood in HIHS with 0.3% 
gametocytemia for a final concentration of 10 μM of NPC1161B. 
Similarly, 1 μl of the carrier control was added to 1 ml of 50% 
hematocrit infected blood in HIHS with 0.3% gametocytemia. 
The experimental group of An. stephensi mosquitoes was fed on 
300 μl of the NPC1161B-treated blood by SMFA to be infected 
and treated simultaneously. The control group of An. stephensi 
mosquitoes was fed on 300 μl of the carrier-treated blood by 
SMFA to be infected and treated simultaneously.
Oocyst Quantification
An. stephensi midguts were dissected on day 8 post-infection 
and stained with 0.1% mercurochrome in PBS for 10 min. Then, 
midguts were washed in PBS, arranged on a 3” × 1” microscope 
slide in 12 μl of PBS and covered with a 22 × 22 mm cover slip 
sealed with paraffin. The 5× objective was used with a 10× lens to 
visualize the midguts and oocysts. Each midgut was imaged with 
Progress Capture Pro software, ensuring oocysts in all planes 
were visible. ImageJ and ProgRes CapturePro Software were 
used to count oocyst number per midgut and to measure oocyst 
diameter. All data were blinded. Mann–Whitney and unpaired 
t-tests were run using GraphPad (GraphPad Software, Inc., La 
Jolla, CA).
Sporozoite Quantification
The salivary glands of each mosquito were dissected into 100 μl 
of PBS on day 14–15 post-infection. Each sample was centrifuged 
at 1,200 × g for 3 min and homogenized to release the sporozoites 
from the salivary glands using a sterile micro-pestle. Samples 
were vortexed and centrifuged again. Sporozoites were counted 
blindly on a hemocytometer by averaging two fields. Kruskal–
Wallis and two-tailed t-tests were run using GraphPad.
Immunofluorescence Assay Of 
Whole Midguts
An. stephensi midguts were dissected on day 12 post-infection 
and fixed in 4% paraformaldehyde for 1 h on ice or overnight 
at 4°C. Midguts were incubated with 3% bovine serum albumin 
(BSA) and 0.1% Triton-X-100 to block and permeabilize for 1 h 
at room temperature or overnight at 4°C. Samples were washed 
in PBS and incubated overnight at 4°C in a 1:1,000 dilution of 
0.5 mg/ml mouse anti-P. falciparum circumsporozoite protein 
[PfCSP; 2A10; MRA183A, Malaria Research and Reference 
Reagent Resource Center (MR4), Bei Resources], in 3% BSA. 
Following incubation with the primary antibody, midguts were 
washed in PBS and incubated for 1 h in a 1:1,000 dilution of 2 mg/
ml Alexa Fluor goat anti-mouse 594 antibody (Life Technologies, 
Frederick, MD) in 3% BSA while being protected from light. 
Following incubation with the secondary antibody, midguts 
were washed in PBS, deposited on a slide in a drop of ProLong 
Diamond Antifade Reagent with DAPI (Life Technologies, 
Frederick, MD), and covered with a 22 × 22 mm coverslip. 
Slides were viewed and imaged using a Nikon Upright E800, 
Nikon 90i, or Zeiss Axioskop2 microscope and the GNU Image 
Manipulation Program (GIMP).
Determination Of NCP1161B Metabolites
An. stephensi and An. gambiae mosquitoes were fed in an SMFA 
using blood dosed with 10 µM NPC1161B or an equal volume 
of drug carrier. Forty-eight hours after blood feeding, both 
drug-treated and control midguts were dissected into tubes 
containing cold HPLC-grade methanol (MeOH) and placed 
on ice. Following dissection, metabolites were extracted from 
midguts (n = 10) by sonication with a microtip probe. Sonication 
parameters consisted of three pulses of 10 s with a 30 s rest period 
between each, power set to 20%, and a frequency setting of 7 
(Branson Sonifier 450). The samples were kept on ice throughout 
the sonication process to minimize heat degradation. Following 
sonication, an equal volume of cold HPLC-grade water was added 
to each tube, and the sample was vortexed vigorously. Proteins 
were precipitated following the addition of cold acetone and 
overnight incubation at −80°C. Samples were then centrifuged at 
17,000 × g for 5 min to pellet the proteins; the supernatant was 
transferred to new tubes, dried using a SpeedVac, and stored at 
−80°C until analysis. RBCs were also incubated with NPC1161B 
alone for up to 48 h; then, metabolite extraction was performed 
using the same protocol to control for potential metabolism of 
the drug unrelated to the midgut.
Prior to analysis of midgut-extracted metabolites, optimization 
of ion transitions for the parent compound NPC1161B was 
performed using product ion mass spectrometry. A standard 
solution of NPC1161B at 1 mg/ml concentration was serially 
diluted into 50% MeOH, then injected onto an Agilent RRHT 
C18 column (50 mm × 2.1 mm) using an Agilent 1290 Infinity 
II UHPLC system consisting of binary pump, autosampler, and 
temperature-controlled column compartment. The autosampler 
maintained the samples at +4°C during analysis, and the column 
was kept at 30°C. Solvents consisted of water + 0.1% formic acid 
(FA) as solvent A and acetonitrile (ACN) + 0.1% FA as solvent 
B, with a flow rate of 600 µl/min. Compounds were eluted from 
the column using a gradient program as follows: 0–0.5 min 2% B, 
ramping to 95% B over 3.5 min, and holding at 95% B for 0.5 min 
before returning to 2% B for re-equilibration, with a total time 
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of 5 min. Eluted compounds were analyzed by an Agilent 6495 
triple quadrupole mass spectrometer (QqQ-MS). The system 
was operated in positive ion mode, with a source temperature 
of 250°C, gas flow of 15 L/min, sheath gas temperature of 350°C, 
sheath gas flow of 11 L/min, and capillary and nozzle voltages of 
3,500 V and 500 V, respectively. Product ion scan mode was used, 
with the optimization of parameters for collision energy and 
selection of fragment ions determined using Agilent Optimizer 
Software. The first quadrupole was set to select for the precursor 
ion 434.2 m/z with an isolation width of 0.7 m/z, while the third 
quadrupole was set to full scan mode between 35 and 500 m/z. 
The entire system was controlled using Agilent MassHunter 
Acquisition software.
Analysis of metabolites extracted from midguts was performed 
using the same system as described above, with the following 
changes. A Waters Acquity HSS C18 column (150 mm × 2.1 mm) 
was used, the column was maintained at 50°C, and the following 
gradient was used: 0–2 min 2% B, ramping to 95% B over 24 
min, holding at 95% B for 2 min before returning to 2% B for 
re-equilibration, with a total time of 30 min. The solvent system 
and flow were as described above. Source parameters were the 
same as above, but precursor ion scan mode was used. The first 
quadrupole was set to full scan mode between 100 and 600 m/z, 
while the third quadrupole was set to selectively monitor three 
ions representing fragments of the parent compound NPC1161B 
(203.2, 215.1, and 334.0 m/z, respectively). CID with N2 gas was 
done at 42 eV, with a cell accelerator voltage of 5 V, as optimized 
previously on the standard. A dwell time of 200 ms for each 
product ion was used, and the fragmenter was fixed at 380 V.
High resolution mass spectrometry analysis for NPC1161B 
and midgut metabolites was performed using the same LC 
system, column, and gradient as above. Eluted compounds were 
analyzed by an Agilent 6550 quadrupole time-of-flight mass 
spectrometer (Q-ToF-MS). The system was operated in positive 
ion mode, with the same source parameters as described above. 
Targeted MS/MS was used to collect fragmentation data with 
the following parameters: MS1 data were collected from 50 to 
1,000 m/z at 1 spectra/s, and MS2 data were collected from 35 to 
500 m/z at 3 spectra/s. Fragmentation was done by CID at 42 eV 
as before, with the quadrupole isolation width set to 1.3 m/z. 
Both 24- and 48-h post-blood feedings were analyzed, but we 
found that the parental compound NPC1161B remained in high 
abundance after 24 h. We therefore focused our analyses at 48 h, 
which coincides with the physiological completion of midgut 
blood digestion and is likely when the majority of NPC1161B 
metabolites can be found in the midgut.
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